johnnyp
Active member
- Awards
- 1
http://www.prnewswire.com/news-releases/viking-therapeutics-presents-phase-1-data-and-highlights-ongoing-phase-2-study-of-vk5211-at-5th-fragility-fracture-network-global-congress-2016-300321283.html
"The Phase 2 trial is a randomized, double-blind, placebo-controlled, parallel group study designed to evaluate the efficacy, safety and tolerability of VK5211 in up to 120 patients recovering from hip fracture surgery. Patients who suffered a hip fracture in the prior four-to-twelve weeks are being randomized to receive once-daily oral VK5211 doses of 0.5 mg, 1.0 mg, 2.0 mg, or placebo for 12 weeks. The study's primary endpoint is the evaluation of the effects of VK5211 on lean body mass after 12 weeks of treatment. Secondary and exploratory objectives include assessments of functional performance, quality-of-life, and activities of daily living, as well as safety, tolerability and pharmacokinetics."
"The Phase 2 trial is a randomized, double-blind, placebo-controlled, parallel group study designed to evaluate the efficacy, safety and tolerability of VK5211 in up to 120 patients recovering from hip fracture surgery. Patients who suffered a hip fracture in the prior four-to-twelve weeks are being randomized to receive once-daily oral VK5211 doses of 0.5 mg, 1.0 mg, 2.0 mg, or placebo for 12 weeks. The study's primary endpoint is the evaluation of the effects of VK5211 on lean body mass after 12 weeks of treatment. Secondary and exploratory objectives include assessments of functional performance, quality-of-life, and activities of daily living, as well as safety, tolerability and pharmacokinetics."
